Patents by Inventor Michael J. Bjorn

Michael J. Bjorn has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Monoclonal anti-human breast cancer antibodies
    Patent number: 5629197
    Abstract: Murine monoclonal antibodies are prepared and characterized which bind selectively to high molecular weight mucins by immunoprecipitation test and are IgGs or IgMs. Immunotoxins comprising the monoclonal antibody and cytotoxic moiety were produced.
    Type: Grant
    Filed: August 11, 1994
    Date of Patent: May 13, 1997
    Assignee: Cetus Oncology Corporation
    Inventors: David B. Ring, Arthur E. Frankel, Michael J. Bjorn
  • Anti-human ovarian cancer immunotoxins and methods of use thereof
    Patent number: 4958009
    Abstract: Immunotoxins comprising a cytotoxic moiety and monoclonal antibodies which bind to human ovarian cancer tissue having at least one of the following capabilities are claimed: cytotoxic ID.sub.50 of 10 nM or less against human ovarian cancer cells, retardation of human ovarian cancer tumor growth in mammals or extension of survival of a mammal carrying a human ovarian cancer tumor. Antigens to which the monoclonal antibody of the immunotoxin bind are identified and characterize the immunotoxins. Methods of killing human ovarian cancer cells, retarding the growth of human ovarian cancer tumors in mammals or extending the survival of mammals carrying human ovarian cancer tumors are claimed.
    Type: Grant
    Filed: July 6, 1987
    Date of Patent: September 18, 1990
    Assignee: Cetus Corporation
    Inventors: Michael J. Bjorn, David J. FitzGerald, Arthur E. Frankel, Walter J. Laird, Ira H. Pastan, David B. Ring, Mark C. Willingham, Jeffrey L. Windelhake
  • Anti-human ovarian cancer immunotoxins and methods of use thereof
    Patent number: 4956453
    Abstract: Immunotoxins comprising a cytotoxic moiety and an antigen binding portion selected from the group consisting of Fab, Fab' and F(ab').sub.2 fragments of a monoclonal antibody, which binds to human ovarian cancer tissue, having one of the following capabilities are claimed: cytotoxic ID.sub.50 of about 10 nM or less against human ovarian cancer cells, retardation of human ovarian cancer tumor growth in mammals, or extension of survival of a mammal carrying a human ovarian cancer tumor. Antigens or epitopes to which the monoclonal antibodies bind are identified and characterize the immunotoxins. In a preferred embodiment an immunotoxin comprising at least an antigen binding portion of a monoclonal antibody, which binds to human transferrin receptor, but does not block binding of transferrin to the receptor, is described and claimed. Immunotoxin comprising the F(ab').sub.2 region of the antitransferrin monoclonal antibody are also claimed.
    Type: Grant
    Filed: July 6, 1987
    Date of Patent: September 11, 1990
    Assignee: Cetus Corporation
    Inventors: Michael J. Bjorn, Arthur E. Frankel, Walter J. Laird, David B. Ring, Jeffrey L. Winkelhake
  • Monoclonal anti-human breast cancer antibodies
    Patent number: 4753894
    Abstract: Murine monoclonal antibodies are prepared and characterized which bind selectively to human breast cancer cells, are IgGs or IgMs, and when conjugated to ricin A chain, exhibit a TCID 50% against at least one of MCF-7, CAMA-1, SKBR-3, or BT-20 cells of less than about 10 nM. Methods for diagnosing, monitoring, and treating human breast cancer with the antibodies or immunotoxins made therefrom are described.
    Type: Grant
    Filed: January 11, 1985
    Date of Patent: June 28, 1988
    Assignee: Cetus Corporation
    Inventors: Arthur E. Frankel, David B. Ring, Michael J. Bjorn